An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-beta in human breast cancer

Conclusions: Tumor suppressive effects of TGF-beta persist in some breast cancer patients at the time of surgery and affect clinical outcome. Carefully tailored in vitro/in vivo genomic approaches can identify such patients for exclusion from treatment with TGF-beta antagonists.

http://breast-cancer-research.com/content/16/3/R57

Source: Breast Cancer Research - June 2, 2014 Category: Cancer & Oncology Authors: Misako SatoMitsutaka KadotaBinwu TangHoward YangYu-an YangMengge ShanJia WengMichael WelshKathleen FlandersYoshiko NaganoAleksandra MichalowskiRobert CliffordMaxwell LeeLalage Wakefield Source Type: research

More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Genetics